Medical News

RSS

Exactech commences clinical trial to evaluate new cartilage repair technology

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials announced today it has initiated a prospective, randomized, multi-center, clinical trial to evaluate the safety and effectiveness of a new cartilage repair technology.

19 Dec 2011

Health panel under fire for screening advice

The U.S. Preventive Services Task Force is right on the firing line. For much of its 27-year history, it helped convince millions of Americans to get screened early for disease.

19 Dec 2011

UCL awarded 20M grant to establish The Leonard Wolfson Experimental Neurology Centre

A new centre dedicated to the understanding and treatment of neurodegenerative diseases will be established at UCL following the award of a -20million grant from the Wolfson Foundation, it was announced today.

19 Dec 2011

Fluoride supplements not found to be safe or effective

According to the Cochrane Oral Health Group, fluoride supplements fail to reduce tooth decay in primary teeth, permanent teeth cavity-reduction is dubious and health risks are little studied.

19 Dec 2011

Political cartoon: 'Reindeer Games?'

Kaiser Health News provides a fresh take on health policy developments with "Reindeer Games?" by Clay Bennett.

19 Dec 2011

Delaware Court upholds original ruling in favor of PharmAthene

PharmAthene, Inc. today announced that the Delaware Court of Chancery has denied SIGA Technologies' motion for reargument filed on October 4, 2011, upholding the Court's original September 22, 2011 decision awarding PharmAthene 50% of the net profits over ten years from all sales of SIGA's smallpox antiviral therapeutic, ST-246, and related products, after SIGA receives the first $40 million in net profits.

19 Dec 2011

MDA doctors challenge breast cancer brachytherapy study

A recent study on a sophisticated form of radiation treatment for breast cancer is inaccurate and has caused unnecessary concern among many patients, according to four top physician researchers.

19 Dec 2011

HA fillers will see highest growth among facial injectable products in 2013 rebound

According to Millennium Research Group, the global authority on medical technology market intelligence, poor economic conditions will limit growth of the European facial injectables market in 2011 and 2012 down to 2.5 percent per year, but the market will rebound strongly in 2013 and onward, reaching a rate of nearly 12 percent by 2016, for a total market of $420 million.

19 Dec 2011

Second-hand smoke exposure during childhood associated with aspirin-exacerbated respiratory disease

Need another reason to keep your New Year's resolution to stop smoking? A first-of-its-kind study found adults with aspirin-exacerbated respiratory disease were more than three times as likely to have been exposed to second-hand smoke during childhood as those without the condition.

19 Dec 2011

Gulf War illness research get $10 million boost

Congress has approved dedicating $10 million to research the mysterious Gulf War illness, ending concerns from veterans' groups that the money would disappear because of budget problems.

19 Dec 2011

Studies confirm potential of EarlySense system as risk assessment tool for preventing pressure ulcers

EarlySense, a market leader in proactive patient care solutions, announced today post regulatory approval clinical and interventional study results further confirming the EarlySense contact-free patient monitoring system's high value as a risk assessment tool for preventing pressure ulcers.

19 Dec 2011

Affordable artemisinin using tobacco plants

Combating malaria is one of the eight Millennium Development Goals described in the United Nations Millennium Declaration signed by all UN members at the year 2000. A key intervention to control malaria is prompt and effective treatment with artemisinin-based combination therapies.

19 Dec 2011

Newgen acquires novel oncology development programs from Kanion

NewGen Therapeutics, Inc. today announced the acquisition of three novel oncology development programs from Kanion USA, Inc. and Kanion Pharmaceutical Co., Ltd..

19 Dec 2011

Lixte's LB-205 shows therapeutic potential against Gaucher disease

An article in the early edition (December 12, 2011) of the Proceedings of the National Academy of Sciences USA, reported that Lixte's investigational drug, LB-205, was shown to have therapeutic potential in a laboratory model of Gaucher disease.

19 Dec 2011

American Anesthesiology acquires Burlington Anesthesia Associates

American Anesthesiology, a division of MEDNAX, Inc., today announced the acquisition of Burlington Anesthesia Associates, a physician group practice that provides anesthesia services in Mt. Holly, NJ.

19 Dec 2011

GreatCall launches new app to make medication management easy

GreatCall, Inc., a leader in wireless services that enable people to stay connected, safe and healthy, today announced the immediate availability of its first Android OS application, MedCoach—a new app designed to make medication management easy for everyone.

19 Dec 2011

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.

19 Dec 2011

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.

19 Dec 2011

New gel could nip Lyme borreliosis infection in the bud

They come out in the spring, and each year they spread further - the ticks. Thirty percent of them transmit borrelia pathogens, the causative agent of Lyme borreliosis that can damage joints and organs.

19 Dec 2011

Halcyon Healthcare acquires Compassionate Hospice and Altus Healthcare & Hospice

Halcyon Healthcare, a portfolio company of Health Evolution Partners, announced today the completion of two hospice acquisitions in central and northern Georgia. The acquired companies, Compassionate Hospice and Altus Healthcare & Hospice, mark the first two transactions for Halcyon. Halcyon was formed in 2010 by HEP, Dan Kohl and Jack Draughon to build a leading hospice and home health company in the Southeastern U.S.

19 Dec 2011